Brendan Weiss, MD, reports on recent advances in Immunoglobulin light chain (AL) amyloidosis at the 2016 meeting of the American Society of Hematology. He discusses four key areas in 'bending the survival rate': Early diagnosis, ameliorating the light chain cardiotoxicity, achieving deep and lasting clonal remissions, and inducing therapeutic clearance of amyloid. Dr. Weiss also reviews AL amyloidosis trials at Penn Medicine.

Related Links: